Yangshengtang Group, established in 1993, is committed to serve people's healthcare and to provide the sustainable development for the healthcare industry. In 2000, Yangshengtang started to be engaged in the bio-pharmaceutical field. Based on independent R&D of 20 years, biopharmaceuticals has developed as one of pillars of Yangshengtang Group and has gained many achievements: [May 26, 2020] China.org.cn: The coronavirus test kits developed by China is rated as the best by WHO and recommended for global use [May 19, 2020] People’s Daily: 10-year-old girl becomes first recipient of China-made HPV vaccine [Apr. 16, 2020] Sina Finance: INNOVAX, GSK and Xiamen University to jointly develop vaccine against coronavirus [Mar. 17, 2019] Virology of China: China's hepatitis E vaccine is approved for clinical trials in the United States and is fully funded by NIH Now, Yangshengtang takes innovative biological drugs as the Group's next key strategic development goals. We warmly welcome talents from home and abroad join with us to explore the frontier fields and industrialization of medicine.